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Novelty and impact: In a large number of cancer patients, HGF-induced MET signaling is 
exploited by tumor cells as an ‘expedient’ to boost the malignant phenotype and to engender 
drug resistance. We developed a new strategy aimed at concomitant targeting of a ligand and a 
receptor belonging to the same axis. This paper addresses the unmet medical need to treat 
tumors in the absence of MET genetic lesions, a condition in which cancer cells are barely 
sensitive to MET inhibitors. These results may have implications for clinical trials. 
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Abstract 
 
MET, a master gene sustaining ‘invasive growth’, is a relevant target for cancer precision 
therapy. In the vast majority of tumors, wild-type MET behaves as a ‘stress-response’ gene and 
relies on the ligand (HGF) to sustain cell ‘scattering’, invasive growth and apoptosis protection 
(oncogene ‘expedience’). In this context concomitant targeting of MET and HGF could be crucial 
to reach effective inhibition. To test this hypothesis, we combined an anti-MET antibody 
(MvDN30) inducing ‘shedding’ (i.e. removal of MET from the cell surface), with a ‘decoy’ (i.e. the 
soluble extracellular domain of the MET receptor) endowed with HGF-sequestering ability. To 
avoid antibody/decoy interaction -and subsequent neutralization- we identified a single 
aminoacid in the extracellular domain of MET -lysine 842- that is critical for MvDN30 binding, 
and engineered the corresponding recombinant decoyMET (K842E). DecoyMET
K842E
 retains the 
ability to bind HGF with high affinity and inhibits HGF-induced MET phosphorylation. In HGF-
dependent cellular models, MvDN30 antibody and decoyMET
K842E
 used in combination 
cooperate in restraining invasive growth, and synergize in blocking cancer cell ‘scattering’. The 
antibody and the decoy unbridle apoptosis of colon cancer stem cells grown in vitro as 
spheroids. In a preclinical model, built by orthotopic transplantation of a human pancreatic 
carcinoma in SCID mice engineered to express human HGF, concomitant treatment with 
antibody and decoy significantly reduces metastatic spread. The data reported indicate that 
vertical targeting of the MET/HGF axis results in powerful inhibition of ligand-dependent MET 
activation, providing proof of concept in favor of combined target therapy of MET ‘expedience’. 
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Introduction 
 
Metastatic spreading is based on the ability of cancer cells to disrupt cell-to-cell interactions, 
migrate through the extracellular matrix, survive and proliferate in tissues other than their site 
of origin. The physiological counterpart of this complex program – known as ‘invasive growth’ – 
is at the basis of embryogenesis and accounts for wound healing and organ regeneration during 
adult life. Invasive growth is tightly regulated by specific extracellular signals, one of which is 
Hepatocyte Growth Factor (HGF), the ligand for the receptor encoded by MET oncogene
1
. In 
conditions of aberrant activation, HGF/MET signaling drives tumor onset, progression and 
metastasis in a broad spectrum of human malignancies
2
. In a minority of events, MET behaves 
as a ‘driver’ oncogene and tumor cells are dependent on constitutive MET signaling for growth 
and survival (‘MET addiction’). This condition relies on the presence of genetic lesions, mostly 
increased gene copy number
3, 4
 or -less frequently- mutations
5
, that result in constitutive 
ligand-independent receptor activation. In this context, treatment with MET inhibitors is highly 
effective, inducing block of cell proliferation and cell cycle arrest in vitro and inhibition of tumor 
growth in vivo
6, 7
. The co-expression of ligand and receptor within the same cell is another 
strategy exploited by cancer to achieve continuous MET activation, and has been described 
mainly in non-epithelial human cancers, such as osteosarcomas
8
, glioblastomas
9
 and multiple 
myelomas
10
. In most cases, however, aberrant MET activation in tumors originates from 
receptor over-expression, due to transcriptional upregulation of the wild-type gene, triggering 
cancer cell sensitization to ligand stimulation
11
. In the latter case, MET signaling –which results 
in pro-invasive and anti-apoptotic responses– is exploited by cancer cells as a strategy to bypass 
stress conditions and boosts the malignant phenotype (‘MET expedience’
12
). In the absence of 
specific genetic lesions, MET is not strictly necessary for tumor growth, but the presence of the 
ligand sustains receptor activation, enhancing the malignant phenotype. Finally, MET behaves 
as a functional marker of cancer ‘stem-progenitor’ cells in glioblastomas
13, 14
, and supports the 
‘stem’ phenotype in colorectal and breast cancers
15, 16
. Moreover, it has been shown that 
stromal-derived HGF sustains the WNT self-renewal pathway of colorectal cancer stem cells and 
promotes proliferation of colon cancer initiating cells, triggering resistance to anti-EGFR 
therapy
17
. 
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A number of strategies targeting MET or HGF –either small molecule inhibitors, antibodies or 
recombinant proteins- have been designed and are currently under investigation
18, 19
. Among 
them, the MvDN30 antibody is a monovalent chimeric Fab fragment that binds to the 
extracellular domain of MET, inducing proteolytic cleavage (‘shedding’) of the receptor from 
the cell surface
20
. DecoyMET is a recombinant soluble receptor encompassing the whole 
extracellular region of MET; it binds HGF with high affinity and inhibits ligand-driven biological 
activities in vitro and in vivo when expressed by lentiviral vector technology
21
 or as Fc-fusion 
protein
22, 23
. MvDN30  and  decoyMET, used in combination, would allow dual targeting of 
ligand and receptor, acting simultaneously on MET-expressing cancer cells and on HGF-
secreting tumor stroma. We show that vertical inhibition of the MET/HGF axis effectively 
hinders tumor cell growth, motility and invasion in vitro and significantly reduces metastatic 
spreading in vivo, providing proof of concept for combined targeted therapy in a broad 
spectrum of cancers expressing wild-type MET. 
 
Materials and methods 
 
Cell culture 
A549 human lung adenocarcinoma cells, HPAF-II human pancreatic adenocarcinoma cells 
and U87-MG human glioblastoma cells were obtained from ATCC/LGC Standards S.r.l. (Sesto 
San Giovanni, Italy) and cultured as suggested by the supplier. Human metastatic colorectal 
cancer M049 spheroid cultures (courtesy of Carla Boccaccio, University of Torino) were 
maintained as described
15
. M049 three dimensional cultures were established by mechanical 
disaggregation of xenopatient tumors, embedded in Growth Factor Reduced Matrigel (Corning) 
and cultured as described
15
 with the addiction of 2 µM N-acetyl-L-cysteine (Sigma). All cell 
cultures were tested for mycoplasma contamination. 
 
Generation, expression and purification of mutated MET ectodomains 
cDNA sequences of human MET ectodomains (decoyMET) carrying single aminoacid 
substitutions were generated using the QuickChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA). Engineered soluble receptors were produced by transient 
transfection of HEK-293T cells with pcDNA3.1 plasmids (Invitrogen Corporation, Camarillo, CA) 
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expressing cDNAs encoding for wild-type decoyMET or decoyMET mutants, and purified from 
cell supernatants by affinity chromatography using HisTrap HP columns (GE Healthcare, 
Freiburg, Germany) according to manifacturer’s instructions. Large-scale protein production 
and purification were performed by U-Protein Express BV (Utrecht, The Netherlands). 
 
Generation of a tridimensional homology model 
The homology model was built by alignment of MET IPT 3-4 domains (wild-type and 
mutated) with the crystal structure of the top scored homologous Plexin A1 domains 7-10, 
IPT3-IPT6 (PDB 5L7N)24 using SWISS-MODEL software (www.swissmodel.expasy.org). 
 
Immunoprecipitation assays 
To analyze the interaction of wild-type decoyMET or decoyMET mutants with anti-MET 
antibodies, comparable amounts of decoyMET proteins -obtained from cells supernatants as 
described above and normalized according to Western blot analysis- were incubated with DN30 
or DO24 monoclonal antibodies
25
 for 30 minutes at 4°C. Antibody-decoyMET complexes were 
immunoprecipitated with Sepharose-Protein A (GE Healthcare Life Science) and revealed by 
Western blot using HRP-conjugated streptactin (IBA, Goettingen, Germany). Signal was 
detected using ECL System (GE Healthcare). To analyze the interaction of wild-type decoyMET 
or decoyMET
K842E
 with HGF, comparable amounts of decoyMET proteins, obtained and 
normalized as above, were mixed with 1 ml of supernatants from MDA-MB-435 cells 
transduced with a Lentiviral vector expressing human HGF
26
 or supernatants from 
untransduced cells. After 2 h incubation at 4°C, the complexes were immunopreciptated with 
DO24 immobilized on Sepharose-Protein A and revealed by Western blot using the biotinylated 
anti-HGF antibody BAF294 (R&D Systems, Minneapolis, MN) followed by decoration with HRP-
conjugated streptavidin (GE Healthcare). Signal was detected using ECL System (GE Healthcare). 
 
MET phosphorylation assay  
Serum-starved A549 cells were incubated for 24 h with 125 nM MvDN30 or 2 µM 
decoyMET
K842E
, alone or in combination, and then stimulated with 50 ng/ml HGF (R&D Systems) 
for 2 h at 4°C. Total cellular lysates were analyzed by Western blot using the following primary 
antibodies: anti-MET phospho-Tyr
1234/1235
 (D26, Cell Signaling Technology, Beverly, MA); anti-
MET (3D4, Invitrogen Corporation); anti-vinculin (clone hVIN-1, Sigma, Saint Louis, MO). 
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Secondary HRP-conjugated anti-mouse or anti-rabbit IgGs were from Jackson Immuno Research 
(West Grove, PA). Western blot bands were quantified with ImageJ software. PhosphoMET 
signal was normalized on vinculin (loading control. Values obtained were converted in 
logarithmic form, control (HGF-treated sample) subtracted, and represented with heatmaps 
generated by the freeware Gedas program
27
. 
 
Phosphorylation of downstream transducers  
Serum-starved A549 cells were incubated for 24 h with 500 nM MvDN30 or 2 µM 
decoyMETK842E, alone or in combination, and then stimulated with 100 ng/ml HGF (R&D 
Systems) for 15 min at 37°C. Total cellular lysates were analyzed by Western blot using the 
following primary antibodies: anti-ERK phospho-Thr202/Tyr204 (Cell Signaling Technology); 
anti-ERK (Cell Signaling Technology); anti-AKT phospho-Ser473 (Cell Signaling Technology); anti-
AKT (Cell Signaling Technology); anti-GAPDH (D4C6R, Cell Signaling Technology). Secondary 
HRP-conjugated anti-mouse or anti-rabbit IgGs were from Jackson Immuno Research. Western 
blot bands were quantified with ImageJ software. PhosphoERK and phosphoAKT were 
normalized on the corresponding total proteins. Heatmaps were generated as described above. 
 
ELISA Binding Assays 
For analysis of the interaction between decoyMET and the DN30 or DO24 mAbs, affinity-
purified soluble receptors (wild-type decoyMET or decoyMET
K842E
, 100 ng/well) were 
immobilized on ELISA plates and increasing concentrations of the antibodies (0 – 100 nM) were 
added in liquid phase. Binding was revealed using HRP-conjugated anti-mouse antibodies (GE 
Healthcare). For analysis of decoyMET binding to HGF, soluble receptors (50 ng/well) were 
immobilized on ELISA plates pre-coated with the DO24 antibody (100 ng/well) and incubated 
with increasing concentrations of HGF (0-10 nM) in solution. Binding was detected using the 
anti-HGF biotinylated antibody BAF294 (R&D Systems) and revealed with HRP-conjugated 
streptavidin (GE Healthcare). Colorimetric assay was quantified by the multi-label plate reader 
VICTOR-X4 (Perkin Elmer Instruments INC., Whaltman, MA). Data were analyzed and fit using 
Prism software (GraphPad). 
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In vitro biological assays 
For anchorage-independent growth assays, cells were suspended in the appropriate culture 
medium supplemented with 2% FBS and 0.5% Seaplaque agarose (BMA, Rockland, ME), and 
seeded in 48-well plates (500 cells/well) on top of 1% agarose. Fresh medium containing the 
treatments was supplied twice weekly. A549 cells were treated with 1 µM MvDN30 or 1 µM 
decoyMET
K842E
, alone or in combination, in the presence of 30 ng/ml HGF. U87-MG cells were 
treated with 0.5 µM MvDN30 or 1 µM decoyMET
K842E
, alone or in combination. Colonies were 
stained with tetrazolium salts (Sigma) after 12 days of culture. Colony growth was determined 
using Metamorph software (Molecular Devices, Sunnyvale, CA). For cell invasion assays, HPAF-II 
cells (1.5 X 10
5
/well) were suspended in serum-free culture medium in the presence of 0.5 µM 
MvDN30 or 1 µM decoyMET
K842E
, alone or in combination, and seeded on the upper 
compartment of transwell chambers pre-coated with 30 μg/well of Matrigel Matrix (Corning 
Incorporated, NY). Culture medium supplemented with 2% FBS and 12.5 ng/ml HGF was added 
to the lower compartment of the chamber. After 24 h, cells on the upper side of the transwell 
filters were mechanically removed, while cells migrated  through the membrane were fixed 
with 11% glutaraldehyde and stained with 0.1% Crystal Violet. Cell invasion was quantified with 
Image-J software. For cell scattering assays, HPAF-II cells (8000/well) were seeded in 96-well 
plates in complete culture medium. After 6 h, increasing concentrations (0 - 4 µM) of MvDN30 
or decoyMET
K842E
, alone or in 1:1 combination, were added. After additional 24 h, cells were 
stimulated with 6.25 ng/ml HGF for 20 h. Cells were fixed with 11% glutaraldehyde and stained 
with 0.1% Crystal Violet (Sigma-Aldrich). For real-time cell motility assay, HPAF-II cells were 
seeded in E-plates (8000/well; Roche Diagnostics, Mannheim, Germany) and treated as above. 
Electrical impedance was monitored continuously for 48 h, with data recording every ten 
minutes, using a X-Celligence RTCA device (Roche Diagnostic). Values are expressed as cell 
index normalized at the instant of HGF addition. For viability assays, spheroids were seeded in 
96-well plates (1000/well) in stem cell medium in the presence of 20 ng/ml HGF. The following 
day, spheroids were treated with increasing concentrations of MvDN30 or decoyMET
K842E
 (0 - 
700 nM), either alone or in 1:1 combination. After 4 days of treatment, cell number was 
determined using CellTiter-Glo (Promega Corp., Madison, WI) with a VICTOR X4 multi-label 
plate reader (Perkin Elmer). Data were analyzed and fit using Prism software (GraphPad). For 
apoptosis assays, spheroids were seeded as above and treated with 77 nM MvDN30 and 25 nM 
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decoyMET
K842E
 in the presence of 20 ng/ml HGF. Apoptosis was determined after 48 h by the 
free nucleosome method using a Cell Death Detection ELISA
PLUS 
Kit (Roche diagnostics).  
 
Immunofluorescence  
Immunofluorescence analysis on tumor cells and tissues was performed as described
28, 
29
. Staining was done with: anti-MET phospho-Tyr
1234/1235
 primary antibody (D26) revealed by 
Alexa Fluor 555-conjugated secondary antibody; anti-E-cadherin primary antibody (EP700Y, 
Abcam, Cambridge, UK) revealed by Alexa Fluor 488-conjugated secondary antibody; anti-
vimentin primary antibody (VIM 3B4, Merk. Vimodrone, Italy) revealed by Alexa Fluor 555-
conjugated secondary antibody; anti-cleaved Caspase-3  (Asp175) primary antibody (Cell 
Signaling Technology) revealed by Alexa Fluor 488-conjugated secondary antibody. Cells were 
counterstained with 488-conjugated phalloidin (Molecular Probes, USA). All images were 
captured with a Leica TCS SP5 AOBS confocal laser-scanning microscope (Leica Microsystems). 
Immunofluorescence acquisition settings were kept constant within each cell line or tumor 
tissue. Mean Fluorescence Intensity (MFI) was evaluated with ImageJ software, measuring the 
mean pixel intensity in each channel, background subtracted. MFI was normalized on phalloidin 
for cell lines and spheroids and on DAPI for tumors. 
 
In vivo experiments 
All animal procedures were performed according to protocols approved by Ethical 
Committee for animal experimentation of the Fondazione Piemontese per la Ricerca sul Cancro 
and by Italian Ministry of Health. NOD-SCID mice were purchased from Charles River (Calco, 
Italy); hHGF-Ki SCID mice were obtained from AVEO Pharmaceuticals, Cambridge, MA. U87-MG 
cells were  injected subcutaneously (2x106/mouse) in the right flank of female NOD-SCID mice. 
Tumor growth was monitored by caliper measurement twice weekly and tumor volume was 
calculated as previously described30. When the tumors reached a volume of 80-100 mm3 (day 
0), mice were stratified in four homogeneous groups and treated twice weekly by intratumor 
injection with: vehicle (n=10); MvDN30, 12.5 µg (n=9); K842E, 125 µg (n=9); the combination of 
the two (n=10). After 22 days of treatment,  mice were sacrificed and tumors were excised and 
embedded in paraffin for histological analysis. Tumor volume fold increase is calculated as the 
ratio between the value at day 22 and the one at day 0.  HPAF-II cells were transduced with 100 
ng/ml p24 of lentiviral vectors carrying the luciferase gene under the control of the CMV 
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promoter as described
31
. Luciferase-expressing HPAF-II cells (10
4
/mouse) were injected in the 
pancreas of 4- to 6-week-old female hHGF-Ki SCID mice. After two days, mice were injected 
intraperitoneally with XenoLight D-Luciferin (150 mg/kg; Perkin Elmer), stratified into 
homogeneous groups on the basis of the bioluminescence signal using an IVIS Spectrum CT 
apparatus (Perkin Elmer), and randomly assigned to 4 treatment arms: vehicle (n=10); MvDN30 
(10 mg/kg, n=6); decoyMET
K842E
 (10 mg/kg, n=6); MvDN30 + decoyMET
K842E
 (10 + 10 mg/kg , 
n=6). Treatments were administered daily (MvDN30) or every two days (decoyMET
K842E
) by 
intraperitoneal injection. At sacrifice, after five weeks of treatment, tumors and lungs were 
excised. Tumors were embedded in paraffin or OCT and processed for immunohistochemical or 
immunofluorescence analysis, respectively. Proliferation of tumor cells was determined using a 
monoclonal anti-Ki67 antibody (MIB-1, Agilent Technologies) as previously described
32
. Lungs 
were processed for histochemical analysis and micrometastases were evaluated by light 
microscopy on paraffin-embedded, HE-stained non sequential sections. For each mouse, ten 
slides were analyzed; metastatic lesions were scored and their area quantified with ImageJ 
software.  
 
Statistical analysis 
Average, standard deviation (SD) and standard error of the mean (SEM) were calculated 
using Microsoft Office Excel 2010 software (Microsoft Corporation, Redmond, Washington). To 
calculate Kd values, data from ELISA assays were analyzed and fitted according to nonlinear 
regression, one site binding hyperbola curve, using GraphPad Prism software (GraphPad 
Software, San Diego, California).  To calculate IC50 values, data from proliferation assays were 
analyzed and fitted according to nonlinear regression, sigmoidal dose-response curve, using 
GraphPad Prism software. Statistical significance was determined using a two-tailed Student’s t 
test. All experiments were repeated at least three times. The in vivo experiments were 
performed two times. Figures show one representative experiment.  
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Results 
 
Site-directed mutagenesis of the DN30-binding epitope in decoyMET 
To exploit the activity of MvDN30 antibody and decoyMET in combination, it is mandatory to 
prevent interaction between the two molecules, that would result in mutual neutralization. It 
has been shown previously that MvDN30 recognizes an epitope within the IPT-4 domain of MET 
extracellular region at the boundary with the IPT-3 domain
33
. Former studies showed that the 
parental DN30 antibody, that binds the human receptor with picomolar affinity, also interacts 
with dog and rat MET
25, 34
, while it does not cross-react with mouse
20
. Upon alignment of the 
IPT-3 and IPT-4 aminoacid sequences of the above-mentioned mammalian species, a number of 
residues were identified that are selectively changed in the mouse (Fig. 1A). To test if human-
to-mouse swapping of single aminoacid residues could impair antibody binding, soluble 
receptors carrying point mutations in the IPT 3-4 domain were generated and tested against 
the DN30 antibody. Substitution of lysine 842 with glutamic acid generated decoyMET
K842E
, a 
modified soluble receptor not recognized anymore by the antibody, while all other mutations 
did not affect the interaction (Fig. 1B). This mutation did not disrupt the overall structure of the 
protein, in fact decoyMET
K842E
 was immunoprecipitated by DO24, an antibody binding a 
different epitope in the extracellular region of MET
25
 (Fig. 1C). This result was confirmed in 
ELISA assays, performed with affinity-purified decoys in solid phase and antibodies in liquid 
phase (Fig. 1D). The homology model of the IPT 3-4 domains shows that the residue at position 
842 is exposed at the surface. The substitution of lysine with glutamic acid induces an evident 
structural modification, presumably resulting in critical perturbation of the binding site and 
thus hampering decoyMETK842E-antibody interaction (Fig. 1E).  
 
DecoyMET
K842E
 binds HGF with high affinity 
We then investigated if the K842E amino acid substitution interferes with binding of HGF. In 
immunoprecipitation assays, the amount of HGF bound by decoyMET
K842E
 was comparable or 
higher to the amount bound by wild-type decoyMET (Fig. 2A). In ELISA binding assays, the 
affinity constant of decoyMET
K842E
 for HGF (Kd = 1.04  ± 0.05 nM) was superimposable with the 
Kd of 1.44 ± 0.07 nM measured for the wild-type decoyMET (Fig. 2B). Finally, the inhibitory 
activity of decoyMET
K842E 
was tested in an HGF-induced MET phosphorylation assay. As shown 
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in Fig. 2C, wild-type decoyMET and decoyMET
K842E
 inhibited HGF-dependent MET 
phosphorylation in A549 lung cancer cells with comparable potency. Thus, the K842E 
substitution does not interfere with the formation of a stable complex with HGF, and leaves the 
inhibitory activity of the decoy unaffected. 
 
MvDN30 and decoyMET
K842E
 cooperate in inhibition of MET phosphorylation and downstream 
biological responses  
To assess the inhibitory activity elicited by concomitant targeting of the ligand and the 
receptor on MET signal transduction, we tested MET phosphorylation in the presence of 
MvDN30 and decoyMET
K842E
, either alone or in combination. To this end A549 cells, expressing 
a wild-type MET receptor, were stimulated with nanomolar concentrations of HGF and MET 
activation was measured by phosphoMET antibodies. Both molecules displayed inhibitory 
activity, and the combination of the two was more efficient (Fig. 3A). Analysis of downstream 
signaling transducers confirmed that the combination achieved the most effective inhibition of 
ERK and AKT activation (Fig. 3B).  
On the biological ground, MvDN30 and decoyMET
K842E
 in combination strongly inhibited 
anchorage-independent colony growth in cellular models of either autocrine or paracrine HGF 
stimulation. In the former, U87-MG glioblastoma cells -displaying very efficient colony growth 
in soft agar due to a MET/HGF autocrine loop- were inhibited by 75% when MvDN30 and 
decoyMET
K842E
 were used in combination, while colony growth inhibition never exceeded 40% 
when the two molecules were used as single agents (Fig. 3C). Likewise, the combo treatment 
completely blocked the formation of A549 soft agar colonies induced by nanomolar 
concentrations of exogenously-administered HGF, while MvDN30 and decoyMETK842E alone 
achieved a partial though significant inhibition of colony growth (65% and 74%, respectively, 
Fig. 3D). Similar results were obtained in invasion assays performed in Matrigel-coated 
chambers: MvDN30 and decoyMETK842E in combination reduced HGF-driven invasion of HPAF-
II human pancreatic adenocarcinoma cells by 85%, while as single agents achieved only 59% 
and 52% inhibition, respectively (Fig. 3E). In all these biological systems, MvDN30 and 
decoyMET
K842E
 combination impaired MET phosphorylation more efficaciously than the single 
treatments (Suppl. Fig. 1).  
To assess if the effect of the two inhibitors is additive or synergistic, a quantitative motility 
assay was performed. HPAF-II human pancreatic adenocarcinoma cells, expressing wild-type 
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MET, were induced to scatter by HGF. Cell scattering was quantified by measuring the 
variations of electrical impedance of cell-covered electrodes (X-CELLigence Real Time Cell 
Analyzer). The two molecules in combination reduced HGF-dependent cell scattering in dose-
dependent fashion, starting inhibition at 250 nM and achieving complete blockage in the 
micromolar range (Fig. 4 A and B). The Cell Index values measured at the end of the experiment 
(time = 48h) were normalized on HGF (Fig. 4C) and elaborated with the CalcuSYN software to 
assess synergism (Fig. 4D):  for all concentrations examined, the calculated Combination Index 
(CI) was well below 0.5 (CI = 0.1, 0.09, 0.17 and 0.38 for 0.06, 0.25, 1 and 4 µM, respectively),  
indicating that MvDN30 and decoyMET
K842E
 display a synergistic behavior
35
.  
 
MvDN30 and decoyMET
K842E
 impair growth and survival of colon-derived spheroids 
It has been reported that HGF-induced MET activation in colorectal cancer stem cells 
supports the stem phenotype. Moreover, microenvironmental growth factors -including HGF- 
play a role in reducing the sensitivity of cancer-derived stem cells to targeted therapies
36
. Colon 
spheroids -enriched in cancer stem/progenitor cells expressing wild-type MET- were prepared 
from a patient-derived xenograft of colorectal cancer liver metastasis
15
 and tested for growth 
or apoptosis in the presence of exogenous HGF. In the growth assay, the combination of 
MvDN30 and decoyMET
K842E
 reached the inhibitory effect (IC50) at concentrations six to eight 
times lower than the IC50 obtained by single treatments (Fig. 5A). In line with these results, 
treatment by either reagent alone was virtually ineffective in inducing programmed cell death 
at the dose tested, while a strong pro-apoptotic effect was generated by the concomitant 
administration of the two molecules (Fig. 5B). Accordingly, the strongest inhibition of HGF-
induced MET-phosphorylation was obtained by the combined treatment (Fig. 5C).  
 
MvDN30 and decoyMET
K842E
 attenuate the invasive phenotype and reduce metastatic spread  
The inhibitory activity of MvDN30 and decoyMETK842E in combination was assessed in vivo 
in mouse models of ligand-driven MET stimulation.  
The U87-MG glioblastoma xenograft tumor model of autocrine HGF stimulation was 
investigated. Cells were injected subcutaneously in NOD-SCID mice; when tumors reached a 
volume of 80-100 mm3, mice were stratified in homogeneous groups and randomly assigned to 
4 treatment arms: Vehicle, MvDN30, decoyMETK842E or the combination of the two. After 22 
days of treatment, mice were sacrificed and primary tumors excised for histological 
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examination. While the combo treatment induced only a marginal inhibition of growth, 
reduction of phenotypic hallmarks of tumor invasion was observed (Suppl Fig.2).  
The combo treatment was also challenged in a paracrine model of HGF stimulation. As 
previously reported, mouse HGF does not activate the human MET receptor
37, 38
. Hence, to test 
the inhibitory activity of decoyMET
K842E
 in xenografts of human tumors, we exploited a 
transgenic SCID mouse where the mouse HGF gene was replaced by the human gene (hHGF-
Ki)
39
. Human pancreatic adenocarcinoma cells (HPAF-II) were labeled by transduction with the 
luciferase gene and injected orthotopically in the pancreas of hHGF-Ki mice. Engraftment was 
checked by analysis of total body luminescence; mice were stratified into homogeneous groups 
on the basis of bioluminescence values, and randomly assigned to 4 treatment groups: 
VEHICLE, MvDN30, decoyMET
K842E
 or the combination of the two. Tumor growth was 
monitored by total body luminescence (Suppl. Fig. 3A). At sacrifice, 5 weeks after cell injection, 
tumors were excised and analyzed for MET phosphorylation, proliferation, apoptosis and 
vimentin/E-cadherin expression (markers of epithelial-mesenchimal transition). Concurrently, 
lungs were collected for histochemical evaluation of metastatic nodules. The phosphorylated 
status of MET at Tyrosines 1234-1235 was inhibited by either agents, and the combo treatment 
elicited a dramatic effect (Fig. 6A). As expected in this model of MET oncogene ‘expedience’ 
(i.e. expression of wild-type MET), proliferation as well as apoptosis were modestly affected, 
and only by the combo treatment (Suppl. Fig. 3B and C). Analysis of the ratio between vimentin 
and E-cadherin showed that the combination treatment pushed cancer cells towards a more 
epithelial phenotype (Fig. 6B). Accordingly, concomitant administration of MvDN30 and 
decoyMETK842E significantly inhibited MET-driven metastatic dissemination to the lung (Fig. 
6C). 
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Discussion 
 
Pharmacological inhibition of the MET tyrosine kinase receptor in oncogene ‘addicted’ 
cancer cells extinguishes cell proliferation and invasion. Accordingly, patients with MET 
amplified advanced Non-Small Cell Lung Cancer (NSCLC), metastatic gastric or esophageal 
cancer respond to anti-MET therapy
,40,41
. On the other hand, cancer cells without MET genetic 
alterations exploit the ‘physiological’ program triggered by the oncogene as an ‘expedient’ to 
boost the malignant phenotype. ‘Expedience’ requires stimulation of wild-type MET by its 
ligand HGF. In this respect, the contribution of tumor microenvironment to cancer progression 
and metastasis is becoming increasingly relevant, as experimental evidences suggest that the 
malignant phenotype does not develop in a strictly cell-autonomous way, but in a rather 
complex interplay between cancer cells and host stroma
42
. The tumor microenvironment is a 
significant source of HGF, secreted by stromal cells of mesenchymal origin as an inactive 
precursor (proHGF). The latter is stored in the extracellular matrix, thanks to its avidity for 
heparansulfates, and is activated by specific proteases produced either by tumor or stromal 
cells
43
. Therefore, an excess of biologically active ligand is readily available for binding the MET 
receptor and triggers the invasive growth signaling cascade in ‘non-addicted’ cells. This paper 
shows that in conditions of MET ‘expedience’, a concomitant intervention hitting both sides of 
the MET/HGF axis results in improved inhibitory activity. Simultaneous targeting was achieved 
combining a monovalent MET antibody, MvDN30, with a recombinant soluble receptor, 
decoyMET
K842E
. The data provided herein indicate that there is no redundancy in targeting the 
same pathway with complementary tools. We selected the two inhibitors on the basis of their 
mechanisms of action. The antibody induces the physical removal of MET from the cell surface 
by ‘shedding’ of the ectodomain; the latter is released in the extracellular environment and acts 
as ‘decoy’ for HGF. Exogenous supply of recombinant decoyMET reinforces the HGF-
sequestering activity of the endogenous decoyMET generated by MvDN30. To enable the 
concomitant use of MvDN30 and decoyMET, a modified soluble receptor was generated 
(decoyMET
K842E
), deficient in MvDN30 interaction but endowed with high affinity binding 
properties to HGF. The two agents in combination cooperate in a variety of cancer cells, 
reducing the effective therapeutic dose. Moreover, this ‘dual strategy’ displays a strong 
synergistic effect, potentially exerting a superior anti-tumor efficacy. Interestingly, the 
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combination of MvDN30 and decoyMET
K842E
 impairs growth and survival of patient-derived 
colon cancer stem cells expressing MET. MET expression in a sub-population of 
stem/progenitor cancer cells has been defined as MET ‘inherence’
44
, i.e. the physiologic 
(inherent) HGF-induced intracellular response activated in cancer stem cells - in the absence of 
genetic lesions- responsible for resistance to targeted therapies, such as Epidermal Growth 
Factor Receptor (EGFR) inhibitors in colorectal cancer.  The notion linking cancer stem cells and 
resistance to conventional therapies is largely accepted, and the role of microenvironmental 
HGF in maintaining the stem phenotype of MET-expressing progenitor cells is becoming more 
and more established. An effective anti-MET treatment, as the combination of MvDN30 and 
decoyMET
K842E
, could represent a therapeutic support to blunt cancer stem cells and to oppose 
the onset of resistance to targeted therapies. On the other hand, in all cases where MET 
activation is ligand-independent -i.e. in the presence of activating mutations, occurring in solid 
tumors with a frequency of  1-2% (COSMIC database: www.sanger.ac.uk)- the vertical inhibition 
of the MET/HGF axis may be redundant. 
The role of host microenvironment is difficult to investigate in mouse xenografts due to the 
limited cross-reactivity between murine stromal-derived factors and specific targets on human 
cancer cells. This is particularly significant in the case of the HGF/MET system, because murine 
HGF does not activate human MET
37, 38
. The development of genetically modified mouse strains 
expressing the Knocked-in human HGF gene (hHGF-Ki mice) circumvented this problem. In this 
transgenic model, we show that concomitant targeting of environmental HGF and its receptor 
on cancer cells may be an effective therapeutic strategy to hinder malignant progression and 
metastasis.  
Xenografts of pancreatic adenocarcinoma are characterized by precocious metastatic 
dissemination, occurring very early during tumor development, and are sustained by an 
abundant stromal compartment
45,46
. Recently, HGF secreted by pancreatic stellate cells was 
identified as a factor playing a relevant function in tumor-stroma interaction in this type of 
malignancy
47
. In an orthotopic mouse model of human pancreatic adenocarcinoma grafted in 
hHGF-Ki mice, MvDN30 and decoyMET
K842E
 in combination slightly delayed tumor growth, as 
expected in a model of ‘expedience’ where MET is not the driver oncogene. On the other hand, 
the combo treatment proved to be very effective in reducing the metastatic spread, suggesting 
a possible therapeutic application in non-addicted cancer cells featuring wild-type MET.  
16 
 
Epidemiological data show that only 2-3% of epithelial cancers rely on MET oncogenic 
addiction, either because of gene amplification, rearrangement or mutation (COSMIC database: 
www.sanger.ac.uk). For this reason, a number of clinical trials -addressing unselected 
populations of cancer patients- failed
48, 49
. On the other hand, the vast majority of carcinomas 
exploit ligand-dependent wild-type MET activation to unleash the invasive metastatic 
phenotype in response to hypoxia, ionizing radiation or chemotherapy
50-52
. Thus these findings 
suggest that a large cohort of patients -currently unfit to MET targeted therapy due to the 
absence of a specific genetic lesion- should benefit from treatments inspired by the dual 
antibody-decoy strategy, that allows optimal blockade of the HGF-driven MET signaling.  
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Figure legends 
 
Figure 1. Generation of a mutated decoyMET receptor that does not bind the DN30 antibody.  
(A) Comparison of the aminoacid sequences of the third and fourth IPT domains of human, 
mouse, rat and dog MET. Residues that are changed exclusively in the mouse sequence are 
highlighted in red, aminoacids that are changed also (or only) in the rat or dog sequences are 
highlighted in green. Only the IPT-3/IPT-4 boundaries are shown. (B) DecoyMET receptors 
carrying single aminoacid substitutions were incubated with the DN30 antibody. The complexes 
were immunoprecipitated with protein A -that binds to the antibody- and revealed with HRP-
conjugated streptactin -that binds to the strep-tag in the decoy (left panel). 30 µl of normalized 
supernatants used for the immunoprecipitation were run on SDS PAGE to verify decoyMET 
receptors loading (right panel). (C) Wild-type decoyMET or decoyMET
K842E
 were incubated with 
DN30 or DO24 antibodies. The complexes were immunoprecipitated and revealed as in B (left 
panel). 30 µl of normalized supernatants used for the immunoprecipitation were run on SDS 
PAGE to verify decoyMET receptors loading (right  panel). (D) ELISA binding analysis. DN30 mAb 
(left panel) or DO24 mAb (right panel) were in liquid phase, wild-type decoyMET or 
decoyMET
K842E
 in solid phase. Antibody binding was detected using an HRP-conjugated anti-
mouse antibody. OD, optical density at 450 nm. Each point is the mean of values in triplicate ± 
SD. (E) Homology model of MET IPT 3-4 domains (wild-type and mutated). The structure is 
displayed in ‘stick and ball’ mode: IPT 3 yellow, IPT 4 blue. The residues at position 482 (red) are 
displayed in ‘space filling’ mode.  
 
Figure 2. DecoyMET
K842E
 binds HGF at high affinity and inhibits HGF-induced MET 
phosphorylation.  
(A) Wild-type decoyMET or decoyMET
K842E
 were incubated with supernatants from cells 
expressing or not HGF, immunoprecipitated with the anti-MET DO24 antibody and 
immunoblotted with a biotinylated anti-HGF antibody (upper panel). p90, HGF single-chain 
precursor; p60, HGF α-chain; p32-p34, HGF β-chain. The same blot was stripped and re-probed 
with an anti-MET antibody (lower panel). p100, decoyMET. (B) ELISA binding analysis. The DO24 
anti-MET antibody was used to capture wild-type decoyMET or decoyMET
K842E
 in solid phase; 
increasing concentrations of HGF were added in liquid phase. HGF binding was detected using a 
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biotinylated anti-HGF antibody. Each point is the mean of values in triplicate ± SD. (C) HGF-
induced MET phosphorylation. A549 cells were incubated with wild-type decoyMET or 
decoyMET
K842E
 (2 µM) and stimulated with HGF (50 ng/ml). Total cell lysates were 
immunoblotted with anti-phosphoMET (upper panel), anti-vinculin (middle panel) or with anti-
MET antibodies (lower panel). p145, mature form of MET; p117, vinculin; p190, single-chain 
precursor of MET. Heatmaps represent the amount of phosphoMET levels normalized on 
vinculin measured by densitometry.  
 
Figure 3. MvDN30 and DecoyMET
K842E
 cooperate in reducing HGF-induced MET 
phosphorylation and MET-driven biological activities. 
(A) HGF-induced MET phosphorylation. A549 human lung adenocarcinoma cells were incubated 
with 2 µM decoyMETK842E , 125 nM  MvDN30 or the combination of the two, and  stimulated or 
not with 50 ng/ml HGF. Total cell lysates were immunoblotted with anti-phosphoMET (upper 
panel), anti-vinculin (middle panel) or anti-MET antibodies (lower panel). p145, mature form of 
MET; p117, vinculin; p190, single-chain precursor of MET. Heatmaps represent the amount of 
phosphoMET levels normalized on vinculin measured by densitometry. (B) HGF-induced ERK 
and AKT phosphorylation. A549 human lung adenocarcinoma cells were incubated with 500 nM  
MvDN30, 2 M decoyMETK842E or the combination of the two, and stimulated or not with 100 
ng/ml HGF. Total cell lysates were immunoblotted with anti-phosphoERK, anti-ERK, anti-
phosphoAKT, anti-AKT, anti-GAPDH. p42/44, ERK; p60, AKT; p36, GAPDH. Heatmaps represent 
the amount of phosphoprotein levels normalized on the corresponding total proteins measured 
by densitometry. (C) Anchorage-independent growth sustained by autocrine HGF stimulation. 
U87-MG human glioblastoma cells, expressing both HGF and MET proteins, were treated with 
0.5 µM MvDN30 or 1 µM decoyMET
K842E
, alone or in combination. Graph represents percentage 
of average colony growth for each treatment compared to the untreated control. (D) 
Anchorage-independent growth sustained by paracrine HGF stimulation. A549 cells were 
stimulated with 30 ng/ml HGF and treated with 1µM MvDN30 or 1 µM decoyMET
K842E
, alone or 
in combination. Graph represents percentage of average colony growth for each treatment 
compared to the HGF-stimulated control. (E) Transwell invasion assay. HPAF-II human 
pancreatic adenocarcinoma cells were stimulated with 12.5 ng/ml HGF and treated with 0.5 µM 
MvDN30 or 1 µM decoyMET
K842E
, alone or in combination. Graph represents the percentage of 
invasion in comparison to the HGF-stimulated control. Right panel, one representative 
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image/group of the cells migrated through the matrigel layer. n.t., not treated cells. 
Magnification, 200x. Each point is the mean of values in triplicate ± SD. ***= P ≤ 0.001; **= P ≤ 
0.01; * = P ≤ 0.05.  
 
Figure 4. MvDN30 and DecoyMET
K842E
 synergize to inhibit HGF-dependent cell scattering. 
(A) Analysis of cell motility. HPAF-II cells were pre-incubated with different concentrations 
(0.06, 0.25, 1 or 4 µM) of MvDN30 or decoyMET
K842E
, alone or in 1:1 combination, and then 
stimulated with 6.25 ng/ml HGF. Cell scattering was monitored in real time using an X-
CELLigence RTCA device and is expressed as Normalized Cell Index. Each graph refers to one 
treatment concentration. (B) Representative images of HPAF-II cells pre-incubated with 1 µM 
MvDN30 or 1 µM decoyMET
K842E
, alone or in combination, and then stimulated with 6.25 ng/ml 
HGF. n.t., not treated cells.  (C) Cell motility curve. Effect = Cell index values measured at the 
end of the experiment for each dose of treatment, normalized on the values obtained with HGF 
alone and expressed as [1-x]. (D) Drug combination analysis. Values from the cell motility curve 
were elaborated with the Calcusyn software to calculate the Combination Index (CI) for each 
concentration of MvDN30 and decoyMET
K842E
. CI = 1, cooperation; CI <1, synergism; CI>1, 
antagonism.  
 
Figure 5. MvDN30 and DecoyMET
K842E
 in combination strongly impair the growth and survival 
of patient-derived colon cancer spheroids. 
(A) M049 colon spheroids enriched in cancer progenitor cells were pre-incubated with 20 ng/ml 
HGF and treated with increasing concentrations (0-700 nM) of MvDN30 or decoyMET
K842E
, 
alone or in 1:1 combination. The number of viable cells was determined by measuring cellular 
ATP. RLU, Relative Light Unit. AU, Arbitrary Unit. IC50, Inhibitory Concentration 50. Each point is 
the mean of values in triplicate ± SD. (B) M049 cells were pre-incubated with 20 ng/ml HGF, 
treated with 77 nM MvDN30 or 25 nM decoyMET
K842E
, alone or in combination, and processed 
for apoptosis analysis. Programmed cell death was measured by the free nucleasome method. 
Each point is the mean of values in triplicate ± SD and is normalized for cell number. Cell death 
index = free nucleasomes/cell. (C) Analysis of phosphoMET status in M049 cells treated with 
HGF, MvDN30 and decoyMET
K842E
 as in (B). Left panel: representative confocal sections showing 
anti-phosphoMET in red, DAPI in blue (merged in the top row) and phalloidin in green (bottom 
row). Graph on the right reports the Mean Fluorescence Intensity (MFI) of phosphoMET, 
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background subtracted and normalized on phalloidin. Each point is the mean of 5 values ± SEM. 
Bar is 50 µm.  ***= P ≤ 0.001; **= P ≤ 0.01; * = P ≤ 0.05.  
 
Figure 6. MvDN30 and DecoyMET
K842E
 reduce MET phosphorylation and metastatic 
dissemination of pancreatic cancer cells in hHGF-Ki mice.   
Luciferase-expressing HPAF-II cells were injected in the pancreas of hHGF-Ki mice and stratified 
into four homogeneous groups: VEHICLE (n=10), MvDN30 (n=6), decoyMET
K842E
 (n=6), the 
combination of the two (n=6). (A) PhosphoMET status within tumors measured by 
immunofluorescence. Left panel, representative confocal sections showing anti-phosphoMET in 
red and DAPI in blue (merged in the top row). Graph on the right reports the Mean 
Fluorescence Intensity (MFI) of phosphoMET, background subtracted and normalized on DAPI. 
Each point is the mean of 12 values ± SEM. Bar is 50 µm. (B) Evaluation of the EMT phenotype 
of HPAF-II tumors by immunofluorescence analysis of E-cadherin and vimentin expression. Left 
panel, representative images of each experimental group. Anti-E-cadherin in green , anti-
vimentin in red and DAPI in blue. Bar is 50 m. Magnifications of selected fields are shown in 
the insets. Bar is 10 m. Graph on the right reports average values obtained by the analysis of 6 
images per each tumor ± SEM. EMT phenotype is expressed as Vimentin/E-cadherin ratio. (C) 
Metastatic nodules in the lungs evaluated by histochemical HE staining. Graph on the left: 
number of metastatic lesions; each point represents the number of lesions scored for each 
mouse. Graph on the right: area of metastatic lesions; each point represents the average area 
of metastases measured for each mouse. Ten slides/mouse were analyzed; metastatic lesions 
were scored and their area quantified with ImageJ. ***= P ≤ 0.001; **= P ≤ 0.01; * = P ≤ 0.05.  
 









